PLPC-DB™ Oncology Platform | UAE-Incorporated Translational Biotech
PLPC-DB™ ONCOLOGY PLATFORM

An Existing Oncology Platform.
A Defined Path to Institutional Scale.

An existing lyophilized intradermal immunobiology platform with indexed evidence and a structured path to institutional scale.

Product Exists
7 Indexed Papers
UAE-Incorporated

CONFIDENTIAL | INVESTIGATIONAL

The Mission

Transform published science and real-world evidence into a globally trusted oncology platform—UAE-incorporated, internationally developed, and built for global collaboration.

7

Indexed papers

3,572

Exposed patients

512

Structured core

154

PET-FDG subgroup

24,000+

Applications

One Product.
One Programme.
One Governance.

🧴

PLPC-DB™
PRODUCT PLATFORM

Lyophilized acellular processed secretome-derived formulation. Vial • Reconstitution • Intradermal.

👥

ONCOVIX™
CLINICAL PROGRAMME

Supervised selection, timing, integration and follow-up. Built for safety, signals and outcomes.

🗄️

STIP™
EVIDENCE GOVERNANCE

Identity, batch, biomarkers and audit trail. Human-reviewed. Transparent. Traceable.

Published Science.
Real-World Impact.

Published Papers
🧬
IDENTITY

Proteomic fingerprint

🛡️
STABILITY

Processing + lyophilization

🔬
FUNCTION

Tumor-line ex vivo models

📄
TRACEABILITY

STIP™ evidence methods

Human-Data Foundation
Now Being Qualified.

📑
RWD SOURCES

Records • applications
labs • imaging

🗂️
COHORT ACCOUNTING

Deduplication • inclusion
subset mapping

📊
PRESPECIFIED ANALYSIS

Dictionary • endpoints
missingness

QUALIFIED RWE

Recalculation • limitations
human review

OBSERVATIONAL • NONRANDOMIZED • PENDING SOURCE RECONCILIATION

Why UAE?

⚖️
REGULATORY READINESS

UAE regulatory pathway

🏥
INTERNATIONAL CLINICAL NETWORK

Cross-border development capability

Global Collaboration

🌱
PARTNER NETWORK

Global life sciences

🚀
TRANSLATIONAL EXECUTION

Science to market

CLINICAL DEVELOPMENT FOCUS

A broad platform — a disciplined start.

01
PROVISIONAL LEAD

Metastatic refractory melanoma

02
SECOND WORKSTREAM

Metastatic / refractory pancreatic cancer

03
FIRST EXPANSION

Refractory triple-negative breast cancer

TRANSLATIONAL EXECUTION

Cross-border capability. Roles disclosed.

🇦🇪 UAE SPONSOR

OGRD Alliance Biotech
IP • capital • governance

🇨🇱 CHILE CMC

Flowinmunocell
Natalia Muñoz-Godoy

🇪🇸 BARCELONA

BIOEXOCELL • BIOEXOLAB
Translation • feasibility

REGULATORY PATHWAY

Four gates to institutionalisation.

1
PRODUCT TRUTH

Signed definition • TPP • boundary

2
CMC LOCK

Process • CQA • potency • release

3
RWD QUALIFICATION

Cohorts • safety • SAP

BUSINESS MODEL

Partner-led. Evidence-generating.

🤝 CO-DEVELOPMENT

Partner-funded CMC and clinical work

💰 MILESTONES

Development, regulatory and sales

📄 LICENSING

Territory or indication-specific rights

Let’s Build the Next Generation Oncology Biotech Platform

We are seeking strategic partners, specialist investors and development collaborators aligned with evidence-driven oncology innovation and international scale-up.

PLPC-DB™ ONCOLOGY PLATFORM
OGRD Alliance Biotech L.L.C-FZ
UAE-incorporated oncology biotechnology venture
CONFIDENTIAL | INVESTIGATIONAL
Scroll al inicio